Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
about
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer.Prostate cancer vaccines: the long road to clinical application.hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR.Simultaneous inhibition of aryl hydrocarbon receptor (AhR) and Src abolishes androgen receptor signaling.Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt.
P2860
Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Tyrosine kinase inhibitors in ...... step in clinical development.
@en
type
label
Tyrosine kinase inhibitors in ...... step in clinical development.
@en
prefLabel
Tyrosine kinase inhibitors in ...... step in clinical development.
@en
P2093
P2860
P1476
Tyrosine kinase inhibitors in ...... step in clinical development.
@en
P2093
Michelle A Ojemuyiwa
Ravi A Madan
William L Dahut
P2860
P304
P356
10.1517/14728214.2014.969239
P407
P577
2014-10-25T00:00:00Z